Immunic–LifeCare Partners: investment, 201901–201904 financing round totalling €26.7m incl existing investor LCP |
2019-01-07 |
Immunic–Omega Funds: investment, 201901–201904 financing round totalling €26.7m incl investor Omega Funds |
2019-01-07 |
Immunic–Saxony-Anhalt (govt): investment, 201901–201904 financing round totalling €26.7m incl existing investor IBG |
2019-01-07 |
Immunic–SEVERAL: investment, 201901–201904 financing round €26.7m in connection with reverse merger to list on Nasdaq |
2019-01-07 |
Immunic–Vital Therapeutics: investment, 201901–201904 reverse merger to list on Nasdaq with Vital Therapies renamed Immunic Inc |
2019-01-07 |
Loxo Oncology–Lilly: investment, 201901–201902 acquisition cash tender offer $8b for $235/share |
2019-01-07 |
N-of-One–Qiagen: investment, 201901 acquisition €na of N-of-One Inc by Qiagen |
2019-01-07 |
Roche–Exscientia: drug discovery software, 201901– collab up to CHF67m + royalties using Centaur Chemist to design drug candidates |
2019-01-07 |
Biogen–C4 Therapeutics: neurological drugs, 201901– collab strategic up to $415m upfront/milestones discovery small molecues for protein degradation |
2019-01-04 |
Biogen–Skyhawk Therapeutics: neurological drugs, 201901– collab strategic $74m upfront + milestones discovery small molecues using SkySTAR platform |
2019-01-04 |
Medigene–Helmholtz: cell therapy, 201901– license to co-stimulator to enhance TCR therapies for solid tumours from HMGU |
2019-01-04 |
Ribon Therapeutics–Celgene: investment, 201901 financing round Series B totalling $65m incl new + co-investor Celgene Corp |
2019-01-04 |
Ribon Therapeutics–Column Group: investment, 201901 financing round Series B totalling $65m incl existing + co-investor The Column Group |
2019-01-04 |
Ribon Therapeutics–Deerfield: investment, 201901 financing round Series B totalling $65m incl existing + co-investor Deerfield Management |
2019-01-04 |
Ribon Therapeutics–Euclidean Capital: investment, 201901 financing round Series B totalling $65m incl existing + co-investor Euclidean Capital |
2019-01-04 |
Ribon Therapeutics–JnJ: investment, 201901 financing round Series B totalling $65m incl new + co-investorJJDC |
2019-01-04 |
Ribon Therapeutics–Novartis: investment, 201901 financing round Series B totalling $65m incl new + lead investor Novartis Venture Fund |
2019-01-04 |
Ribon Therapeutics–Osage Partners: investment, 201901 financing round Series B totalling $65m incl existing + co-investor Osage University Partners |
2019-01-04 |
Ribon Therapeutics–SEVERAL: investment, 201901 financing round Series B $65m led by Novartis Venture Fund |
2019-01-04 |
Ribon Therapeutics–Takeda: investment, 201901 financing round Series B totalling $65m incl existing + co-investor Takeda Ventures |
2019-01-04 |
Ribon Therapeutics–US Venture Partners: investment, 201901 financing round Series B totalling $65m incl existing + co-investor US Venture Partners |
2019-01-04 |
Sophia Genetics–Alychlo: investment, 201901 financing round Series E totalling $77m incl existing + co-investor Alychlo |
2019-01-04 |
Sophia Genetics–Balderton Capital: investment, 201901 financing round Series E totalling $77m incl existing + co-investor Balderton Capital |
2019-01-04 |
Sophia Genetics–Eurazeo: investment, 201901 financing round Series E totalling $77m incl new + co-investor Idinvest Partners |
2019-01-04 |
Sophia Genetics–Generation Investment Management: investment, 201901 financing round Series E totalling $77m incl new + lead investor Generation |
2019-01-04 |
Sophia Genetics–SEVERAL: investment, 201901 financing round Series E $77m incl new + lead investor Generation Investment Management LLP |
2019-01-04 |
Atriva Therapeutics–High-Tech Gründerfonds: investment, 201901 financing round Series A first closing led by Meneldor + HTGF |
2019-01-03 |
Atriva Therapeutics–MC Services: public relations, 201901 service existent by MC Services |
2019-01-03 |
Atriva Therapeutics–Meneldor: investment, 201901 financing round Series A first closing led by Meneldor + HTGF |
2019-01-03 |
Atriva Therapeutics–SEVERAL: investment, 201901 financing round Series A first closing led by Meneldor + HTGF |
2019-01-03 |
Takeda–Rentschler: biologics contract manufacturing, 201901– supply service continued production for Shire in acquired manufacturing site in Milford |
2019-01-03 |
CARB-X–Germany (govt): grant, 201901–202212 BMBF commits €40m over 4 years |
2019-01-01 |
Curetis–Vienna (govt): grant, 201901–202106 co-funding of developm project of Ares Genetics for AMR assay by Vienna Business Agency |
2019-01-01 |
Delfi Diagnostics–Allianz: investment, 2019 seed financing round totalling $5.5m incl co-investor AV8 Ventures |
2019-01-01 |
Delfi Diagnostics–SEVERAL: investment, 2019 seed financing round $5.5m led by Menlo Ventures |
2019-01-01 |
Marinomed–EU (govt): credit, 20901–2027 up to €15m EIB credit 2019–2022 repayable 2024–2027 |
2019-01-01 |
Medicomp–KLIFO: investment, 2019 acquisition of Medicomp GmbH by KLIFO A/S |
2019-01-01 |
Blink Biomedical–Valneva: investment, 201812 existing shareholding of 43.3% by Valneva consolidated via equity method |
2018-12-31 |
Murdoch Univ–Bruker: mass spectrometer, 2018–201909 supply FIA-MRMS system |
2018-12-31 |
Murdoch Univ–Bruker: mass spectrometer, 2018–201909 supply twelve impact-II UHR-QTOF LC-MS/MS systems |
2018-12-31 |
Murdoch Univ–Bruker: mass spectrometer, 2018–201909 supply two timsTOF Pro LC/CCS/MS/MS systems |
2018-12-31 |
Murdoch Univ–Bruker: NMR spectrometer, 2018–201909 supply seven Avance IVDr 600 NMR systems |
2018-12-31 |
Qiagen–Formulatrix: digital PCR technology, 201812– acquisition of all dPCR assets of Formulatrix for $125m upfront cash + $135m milestones |
2018-12-31 |
Harpoon Therapeutics–SEVERAL: investment, 201812–201902 IPO $76m at $14/share |
2018-12-27 |
AC Immune–WuXi Pharmatech: biologics contract manfucturing, 201812– collab strategic alliance biologics CDMO with WuXi Biologics |
2018-12-19 |
Amgen–Molecular Partners: cancer immunotherapy, 201812– collab $50m upfront + $497m milestones + royalties ww excl developm + commerc rights to MP0310 |
2018-12-18 |
Novartis–Curetis: antibiotics research, 201812– collab Sandoz to use Ares Genetics’ antibiotic resistance database ARESdb |
2018-12-18 |
Versameb–SEVERAL: investment, 201812 closing of seed B financing round brining total capital raised to date to CHF5.3m |
2018-12-18 |
Shire–Rentschler: investment, 201812–201901 acquisition €na of Shire’s manufacturing facility in Milford, MA by Rentschler Biopharma SE |
2018-12-17 |
Noxxon–MC Services: public relations, 201812 service existent by MC Services |
2018-12-14 |
Noxxon–Trophic Communications: public relations, 201812 service existent by Trophic Communications |
2018-12-14 |
Lonza–ERS Genomics: CRISPR technology, 201812– license €na for bioproduction products + services + iPSC research to Lonza Pharma & Biotech |
2018-12-13 |
AC Immune–Lilly: credit, 201812 convertible note $50m in connection with license + collab agreement |
2018-12-12 |
Imprint Analytics–SGS: credit, 201812– convertible loan as part of strategic partnership |
2018-12-12 |
Lilly–AC Immune: tau aggregation inhibitors, 201812– collab + license agreem CHF80m upfront + CHF1.76b milestones + royalties |
2018-12-12 |
SGS–Imprint Analytics: food analysis, 201812– collab strategic partnership isotope analysis for proof of origin + authenticity food testing |
2018-12-12 |
DenovoMatrix–High-Tech Gründerfonds: investment, 201812 seed financing round from HTGF + TGFS |
2018-12-11 |
DenovoMatrix–Saxony (govt): investment, 201812 seed financing round from HTGF + TGFS |
2018-12-11 |
DenovoMatrix–SEVERAL: investment, 201812 seed financing round from HTGF + TGFS |
2018-12-11 |
genOway–Merck (DE): CRISPR technology, 202001– collab strategic alliance extention incl adding non-excl license for all non-rodent animal cell models |
2018-12-10 |
Novartis–Intellia Therapeutics: CRISPR technology, 201812–201912 collab + license agreem expansion incl $10m upfront payment + milestones + royalties |
2018-12-06 |
Merck (DE)–V7: AI software, 201812– collab on software that scientists can use to tag images for future use in training AI software |
2018-12-05 |
Dispendix–Cellink: investment, 201812 acquisition €5m of Dispendix GmbH by Cellink AB |
2018-12-01 |
Resistell–SEVERAL: investment, 201812 seed financing round CHF850k |
2018-12-01 |
Rheostat Therapeutics–SEVERAL: investment, 201811 financing round Series A $23m co-led by MRL Ventures + AbbVie Ventures |
2018-11-26 |
AbbVie–Mission Therapeutics: DUB inhibitors, 201811– collab RnD + license option €na for Alzheimer’s + Parkinson’s diseases |
2018-11-15 |
Cadent Therapeutics–Access Industries: investment, 201811 financing round Series B totalling $40m incl co-investor Access Industries |
2018-11-15 |
Cadent Therapeutics–Atlas Venture: investment, 201811 financing round Series B totalling $40m incl co-lead investor Atlas Venture |
2018-11-15 |
Cadent Therapeutics–Clal Industries: investment, 201811 financing round Series B totalling $40m incl co-investor Clal Biotechnology Industries |
2018-11-15 |
Cadent Therapeutics–Cowen: investment, 201811 financing round Series B totalling $40m incl co-lead investor Cowen Healthcare Investments |
2018-11-15 |
Cadent Therapeutics–Novartis: investment, 201811 financing round Series B totalling $40m incl co-investor Novartis Institutes for Biomedical Research |
2018-11-15 |
Cadent Therapeutics–Qiming: investment, 201811 financing round Series B totalling $40m incl co-investor Qiming Venture Partners |
2018-11-15 |
Cadent Therapeutics–SEVERAL: investment, 201811 financing round Series B $40m co-led by Cowen Healthcare Investments + Atlas Venture |
2018-11-15 |
Virion Biotherapeutics–Trophic Communications: public relations, 201811 service existent by Trophic |
2018-11-14 |
Immunic–Daiichi Sankyo: IMU-856, 201811– license option agreem ww excl to in-license + develop IMU-856 program for IBD |
2018-11-05 |
Psyros Diagnostics–Novartis: point-of-care diagnostics, 201811 acquisition IP + equipment related to Niji point-of-care dx platform from Novartis |
2018-11-01 |
Q-Bioanalytic–Eurofins: investment, 201811 acquisition by Eurofins |
2018-11-01 |
Rheostat Therapeutics–SV Health Investors: investment, <201811 Rheostat incubated + seeded by SV Health Investors + Dementia Discovery Fund |
2018-11-01 |
Galecto–BPCE: investment, 201810 financing round Series C totalling €79m incl new + co-investor Seventure Partners |
2018-10-26 |
XtalPi–SEVERAL: investment, 201810 financing round Series B-1 extension $46m led by China Life Healthcare Fund |
2018-10-24 |
XtalPi–Swiss Investment Group: investment, 201810 financing round Series B-1 extension totalling $46m incl co-investor SIG |
2018-10-24 |
Genome Biologics (DE)–EU (govt): grant, 201810 Horizon 2020 Phase 2 Grant €2.42m |
2018-10-22 |
Kumovis–Ffilipa Venture Capital: investment, 201810 seed financing round totalling 7-digit € incl family office |
2018-10-17 |
Kumovis–High-Tech Gründerfonds: investment, 201810 seed financing round totalling 7-digit € incl investor HTGF |
2018-10-17 |
Kumovis–SEVERAL: investment, 201810 seed financing round 7-digit € from HTGF + Ffilipa Venture Capital |
2018-10-17 |
Atai Life Sciences–SEVERAL: investment, 201810 1st financing round €21.2m from private investors |
2018-10-01 |
Neuron23–SEVERAL: investment, 201810c financing round Series A $33.5m from Westlake Village BioPartners + Kleiner Perkins |
2018-10-01 |
Novaliq–Hopp Group: investment, 201810 financing round €44.9m from Dievini Hopp BioTech Holding GmbH |
2018-10-01 |
Bayer–Inova Software: business development software, 201809 supply existent Bayer is user of Inova Partnering Platform |
2018-09-27 |
Lilly–Inova Software: business development software, 201809 supply existent Lilly is user of Inova Partnering Platform |
2018-09-27 |
Novartis–Inova Software: business development software, 201809 supply existent Novartis is user of Inova Partnering Platform |
2018-09-27 |
Roche–Inova Software: business development software, 201809 supply existent Roche is user of Inova Partnering Platform |
2018-09-27 |
Tolremo Therapeutics–Altos Venture: investment, 201809 financing round Series A totalling CHF9m incl new + co-investor Altos Venture |
2018-09-24 |
Tolremo Therapeutics–BioMedPartners: investment, 201809 financing round Series A totalling CHF9m incl new + lead investor BioMedPartners |
2018-09-24 |
Tolremo Therapeutics–Redalpine: investment, 201809 financing round Series A totalling CHF9m incl new + co-investor Redalpine |
2018-09-24 |
Tolremo Therapeutics–Zürcher Kantonalbank: investment, 201809 financing round Series A totalling CHF9m incl exisintg + co-investor ZKB |
2018-09-24 |
Luciole Medical–Trophic Communications: public relations, 201809 service existent by Trophic Communications |
2018-09-17 |
NeuMoDx–Qiagen: investment, 201809 existent Qiagen owns 19.9% of NeuMoDx |
2018-09-17 |
NeuMoDx–Qiagen: investment, 201809– option to acquire remaining 80.1% of NeuMoDx for $234m |
2018-09-17 |
Qiagen–NeuMoDx: molecular diagnostics, 201809– collab distribution outside US by Qiagen + implementation of Qiagen reagents on NeuMoDex PRC systems |
2018-09-17 |